NasdaqCM:DERMPharmaceuticals
Journey Medical (DERM) Losses Narrow In Q4 EPS Result Tests Bullish Profitability Narrative
Journey Medical (DERM) closed FY 2025 with Q4 revenue of US$16.1 million and a basic EPS loss of US$0.05, while trailing twelve month figures show revenue of US$61.9 million and a basic EPS loss of US$0.47. Over recent quarters, revenue has ranged from US$13.1 million in Q1 2025 to US$17.6 million in Q3 2025, with basic EPS moving between a loss of US$0.18 and a loss of US$0.05. This sets up a story in which top line scale is building while margins remain under pressure.
See our full analysis...